1. Center for Biologics Evaluation and Research (1997) Reinventing the regulation of human tissue. On http://www.fda.gov/cber/tissue/rego.htm Accessed 27/10/05
2. Center for Biologics Evaluation and Research (2002) Preventive measures to reduce the possible risk of transmission of Creutzfeldt–Jakob disease (CJD) and variant Creutzfeldt–Jakob disease (vCJD) by human cells, tissues, and cellular and tissue-based products (HCT/Ps). On http://www.fda.gov/cber/gdlns/cjdvcjd0602.pdf Accessed 27/10/05
3. Center for Biologics Evaluation and Research (2004) Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products: final rule and notice. On http://www.fda.gov/cber/rules/suitdonor.pdf Accessed 27/10/05
4. Center for Biologics Evaluation and Research (2005) Frequently asked questions. On http://www.fda.gov/cber/faq.htm Accessed 27/10/05
5. Centers for Disease Control (2002) Update: allograft-associated␣bacterial infections—United States, 2002. MMWR 51:207–210